Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Bayonne – page 16

196 clinical trials in Bayonne, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bayonne at a glance
196
clinical trials
  • Paediatric trials0
  • Research sites2
Type of trial
Recruitment status
Quick filters

196 trials in Bayonne

Open in trial search

Hepatic cancer

Not recruiting

Study on Adding Ipilimumab to Atezolizumab and Bevacizumab for Patients with Liver Cancer Receiving First-Line Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Non-small cell lung cancer+2

Not recruiting

Study on Atezolizumab, Bevacizumab, and Paclitaxel for Advanced Lung Cancer Patients After Immunotherapy and Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zilovertamab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia

Not recruiting

Study on Azacitidine and Gilteritinib for Adults with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Breast cancer+2

Not recruiting

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer metastatic

Not recruiting

Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Unicancer

Prostate cancer recurrent

Not recruiting

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer AG

Myelodysplastic syndrome

Not recruiting

Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Celgene Corp.

Ovarian cancer+1

Not recruiting

Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MPS-102
  • Sponsor:Arcagy Gineco

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Lenalidomide, and Dexamethasone for Elderly Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Centre Hospitalier Universitaire De Poitiers

Hormone-refractory prostate cancer+1

Not recruiting

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Acute myeloid leukaemia

Not recruiting

Study on Improving Survival in Acute Myeloid Leukemia for Adults Aged 18-60 Using Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cytarabine
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Bayonne

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on multiple myeloma and various types of lymphoma, evaluating novel therapeutic combinations and maintenance strategies.

  • Multiple Myeloma Treatment Innovations
  • Diffuse Large B-Cell Lymphoma Therapies
  • Post-Transplant Maintenance Protocols

Studies are exploring combinations of elranatamab, lenalidomide, and other targeted therapies to improve patient outcomes.

02 Solid Tumors

Comprehensive research into various types of solid cancers, including breast, lung, and colorectal cancers, testing innovative treatment approaches.

  • Advanced Breast Cancer Treatments
  • Non-Small Cell Lung Cancer Therapies
  • Colorectal Cancer Interventions

Trials are evaluating targeted therapies and immunotherapy combinations for better treatment outcomes.

03 Autoimmune Conditions

Innovative studies addressing multiple sclerosis and inflammatory conditions, focusing on treatment optimization and novel therapeutic approaches.

  • Multiple Sclerosis Management
  • Rheumatoid Arthritis Treatments
  • Crohn's Disease Interventions

Research includes de-escalation strategies and combination therapy evaluations.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.